/
Oncology
Relapsed or Refractory Multiple Myeloma
13
Pipeline Programs↗
10
Active Trials↗
12
Companies Involved↗
Relapsed or Refractory Multiple Myeloma is an emerging landscape with 13 programs across 12 companies. The most active players are Johnson & Johnson, AbbVie, Roche. 3 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Phase 17
Phase 2
No programs
Phase 33
Approved
No programs
Analysis
Modality Breakdown
12programs
Small molecule650%
Monoclonal antibody433%
Protein / enzyme18%
RNA therapy18%
Modality classified for 92% of 13 pipeline programs.
Analysis
Trial Status
11
clinical trials
Recruiting7 · 64%
Active, not recruiting2 · 18%
Completed1 · 9%
Not yet recruiting1 · 9%
Clinical Trials
Trial Activity
11 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)